太龍藥業(600222.SH)擬對3家全資子公司增資
格隆匯3月27日丨太龍藥業(600222.SH)公佈,為壯大全資子公司桐君堂藥業資本實力,進一步提升公司中藥飲片業務市場競爭力,擴大中藥優質道地藥材的採購、倉儲及供應能力;同時加大中藥代煎藥服務設施的投入,提升綜合服務能力及品質,公司擬向桐君堂藥業增資5500萬元(其中增加註冊資本5440萬元,增加資本公積60萬元),本次增資完成後,桐君堂藥業的註冊資本由1.956億元增至2.5億元,仍為公司全資子公司。
桐君堂藥業為擴大其全資子公司桐君堂飲片公司的中藥飲片加工規模,增強競爭力,擬向其增資5500萬元,本次增資完成後,桐君堂飲片公司的註冊資本由6500萬元增至1.2億元,仍為桐君堂藥業的全資子公司。
為進一步增強全資子公司北京新領先在研發行業的競爭優勢以及抵抗風險能力,把握市場機遇,完善其業務資源體系,為其發展提供更大的資金支持,公司擬向北京新領先增資5800萬元,本次增資完成後,北京新領先的註冊資本由2200萬元增至8000萬元,仍為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.